middle.news
Cambium Bio Clears FDA to Launch Phase 3 Trials for Dry Eye Therapy
9:17am on Friday 11th of July, 2025 AEST
•
Healthcare
Read Story
Cambium Bio Clears FDA to Launch Phase 3 Trials for Dry Eye Therapy
9:17am on Friday 11th of July, 2025 AEST
Key Points
FDA clearance obtained for Phase 3 dosing of Elate Ocular
Manufacturing changes validated through extensive comparability program
Ethics approvals secured in Australia and the US
Trial protocols finalized following FDA consultation
Read Story
middle.
Tap to Read
Tap the card to read the full analysis
about
Cambium Bio (ASX:CMB)
OPEN ARTICLE